...disease play Anacor Pharmaceuticals Inc. (NASDAQ:ANAC); a $20 million senior credit facility for ophthalmic company NeoVista Inc....

...secured $20 million in a senior credit facility from Oxford Finance Corp. and GE Capital. NeoVista Inc....

...Calif.) secured $20 million in a credit facility from Oxford Finance Corp. and GE Capital. NeoVista's...

...Ophthalmic company NeoVista Inc. (Fremont, Calif.) raised $33.8 million in a series E round from Versant Ventures...
...from Versant Ventures; Accuitive Medical Ventures; Carlyle Venture Partners; SV Life Sciences; and MPM Capital. NeoVista's...

...photodynamic therapy, Photrex rostaporfin, is in Phase III testing to treat CNV associated with AMD. NeoVista Inc.'s...

...on both fronts. While most biotechs in the space are focused on me-better VEGF treatments, NeoVista Inc....
...per dose and most patients need injections every 4-6 weeks for at least two years. NeoVista...
...non-inferior to Lucentis, then Epi-Rad90's cost benefits over Lucentis alone might become irrelevant. Radiation therapy NeoVista...